Protection of rhesus monkeys from fatal Lassa fever by vaccination with a recombinant vaccinia virus containing the Lassa virus glycoprotein gene.

PubWeight™: 1.25‹?› | Rank: Top 10%

🔗 View Article (PMC 286455)

Published in Proc Natl Acad Sci U S A on January 01, 1989

Authors

S P Fisher-Hoch1, J B McCormick, D Auperin, B G Brown, M Castor, G Perez, S Ruo, A Conaty, L Brammer, S Bauer

Author Affiliations

1: Centers for Disease Control, Atlanta, GA 30333.

Articles citing this

Development of a new vaccine for the prevention of Lassa fever. PLoS Med (2005) 2.71

Imported lassa fever in Germany: molecular characterization of a new lassa virus strain. Emerg Infect Dis (2000) 2.69

Effective vaccine for lassa fever. J Virol (2000) 1.74

Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J Virol (2001) 1.66

Animal Models for the Study of Rodent-Borne Hemorrhagic Fever Viruses: Arenaviruses and Hantaviruses. Biomed Res Int (2015) 1.43

Characterization of human CD4(+) T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein. J Virol (2000) 1.24

Detection of Lassa virus antinucleoprotein immunoglobulin G (IgG) and IgM antibodies by a simple recombinant immunoblot assay for field use. J Clin Microbiol (1998) 1.24

Identification of a broad-spectrum arenavirus entry inhibitor. J Virol (2008) 1.23

Pathogenesis of Lassa fever in cynomolgus macaques. Virol J (2011) 1.16

Identification of protective Lassa virus epitopes that are restricted by HLA-A2. J Virol (2006) 1.07

Cross-protection against lymphocytic choriomeningitis virus mediated by a CD4+ T-cell clone specific for an envelope glycoprotein epitope of Lassa virus. J Virol (1993) 1.06

Vaccinia virus vectors: new strategies for producing recombinant vaccines. Clin Microbiol Rev (1990) 0.92

Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever. Virol J (2010) 0.92

Mucosal immunization with Salmonella typhimurium expressing Lassa virus nucleocapsid protein cross-protects mice from lethal challenge with lymphocytic choriomeningitis virus. J Hum Virol (2001) 0.91

Advanced vaccine candidates for Lassa fever. Viruses (2012) 0.90

Mucosal arenavirus infection of primates can protect them from lethal hemorrhagic fever. J Med Virol (2004) 0.88

Molecular characterization of a reassortant virus derived from Lassa and Mopeia viruses. Virus Genes (2006) 0.88

An attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity. Virol J (2013) 0.86

Comparative pathogenesis and systems biology for biodefense virus vaccine development. J Biomed Biotechnol (2010) 0.82

Current approaches to vaccine preparation. Can Vet J (1990) 0.79

Enhanced Efficacy of a Codon-Optimized DNA Vaccine Encoding the Glycoprotein Precursor Gene of Lassa Virus in a Guinea Pig Disease Model When Delivered by Dermal Electroporation. Vaccines (Basel) (2013) 0.76

Articles cited by this

Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65

Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A (1979) 365.71

Rapid isolation of antigens from cells with a staphylococcal protein A-antibody adsorbent: parameters of the interaction of antibody-antigen complexes with protein A. J Immunol (1975) 47.77

Enzyme-linked immunoelectrotransfer blot techniques (EITB) for studying the specificities of antigens and antibodies separated by gel electrophoresis. Methods Enzymol (1983) 6.86

Lassa fever. Effective therapy with ribavirin. N Engl J Med (1986) 6.38

A prospective study of the epidemiology and ecology of Lassa fever. J Infect Dis (1987) 5.27

Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc Natl Acad Sci U S A (1983) 4.69

Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc Natl Acad Sci U S A (1986) 4.14

Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone. Science (1974) 3.86

A case-control study of the clinical diagnosis and course of Lassa fever. J Infect Dis (1987) 3.51

Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. Proc Natl Acad Sci U S A (1984) 2.85

Comparative pathology of Lassa virus infection in monkeys, guinea-pigs, and Mastomys natalensis. Bull World Health Organ (1975) 1.83

Nucleotide sequence of the glycoprotein gene and intergenic region of the Lassa virus S genome RNA. Virology (1986) 1.69

Isolation of an arenavirus closely related to Lassa virus from Mastomys natalensis in south-east Africa. Bull World Health Organ (1977) 1.53

A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy. BMJ (1988) 1.51

Epidemiology and control of Lassa fever. Curr Top Microbiol Immunol (1987) 1.40

Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys. J Infect Dis (1984) 1.30

Physiological and immunologic disturbances associated with shock in a primate model of Lassa fever. J Infect Dis (1987) 1.20

Protection of rhesus monkeys from Lassa virus by immunisation with closely related Arenavirus. Lancet (1979) 1.14

Construction of a recombinant vaccinia virus expressing the Lassa virus glycoprotein gene and protection of guinea pigs from a lethal Lassa virus infection. Virus Res (1988) 1.11

Articles by these authors

(truncated to the top 100)

Lassa fever. Effective therapy with ribavirin. N Engl J Med (1986) 6.38

Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nat Med (1999) 5.85

A prospective study of the epidemiology and ecology of Lassa fever. J Infect Dis (1987) 5.27

Human asymptomatic Ebola infection and strong inflammatory response. Lancet (2000) 5.20

Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science (1998) 5.05

Ebola virus disease in southern Sudan: hospital dissemination and intrafamilial spread. Bull World Health Organ (1983) 4.81

Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci U S A (1996) 4.69

An activating immunoreceptor complex formed by NKG2D and DAP10. Science (1999) 4.56

A sperm ion channel required for sperm motility and male fertility. Nature (2001) 4.43

Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A (1999) 4.40

Longitudinal cohort study of the epidemiology of malaria infections in an area of intense malaria transmission II. Descriptive epidemiology of malaria infection and disease among children. Am J Trop Med Hyg (1999) 4.24

A case-control study of the clinical diagnosis and course of Lassa fever. J Infect Dis (1987) 3.51

Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. BMJ (1995) 3.21

Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A (2005) 3.20

Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet (1997) 3.08

Protein kinase C phosphorylates the inhibitory guanine-nucleotide-binding regulatory component and apparently suppresses its function in hormonal inhibition of adenylate cyclase. Eur J Biochem (1985) 3.04

Lumen diameter of normal human coronary arteries. Influence of age, sex, anatomic variation, and left ventricular hypertrophy or dilation. Circulation (1992) 2.98

Clinical virology of Lassa fever in hospitalized patients. J Infect Dis (1987) 2.94

A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med (1997) 2.84

Primary gastric B-cell lymphoma: results of a prospective multicenter study. The German-Austrian Gastrointestinal Lymphoma Study Group. Gastroenterology (2000) 2.65

Descriptive analysis of Ebola virus proteins. Virology (1985) 2.65

Lassa fever in the United States. Investigation of a case and new guidelines for management. N Engl J Med (1990) 2.57

Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol (1999) 2.57

Inactivation of Lassa, Marburg, and Ebola viruses by gamma irradiation. J Clin Microbiol (1982) 2.44

Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arterioscler Thromb Vasc Biol (2001) 2.42

Influence of coronary collateral vessels on myocardial infarct size in humans. Results of phase I thrombolysis in myocardial infarction (TIMI) trial. The TIMI Investigators. Circulation (1991) 2.33

Unsafe injections and the transmission of hepatitis B and C in a periurban community in Pakistan. Bull World Health Organ (2000) 2.33

The relationship between therapeutic injections and high prevalence of hepatitis C infection in Hafizabad, Pakistan. Epidemiol Infect (1997) 2.27

Pathologic and virologic study of fatal Lassa fever in man. Am J Pathol (1982) 2.14

Effects of prolonged intensive lipid-lowering therapy on the characteristics of carotid atherosclerotic plaques in vivo by MRI: a case-control study. Arterioscler Thromb Vasc Biol (2001) 2.14

The risks of blood transfusion: the relative influence of acquired immunodeficiency syndrome and non-A, non-B hepatitis. Am J Med (1992) 2.12

Ribavirin suppresses replication of lymphadenopathy-associated virus in cultures of human adult T lymphocytes. Lancet (1984) 2.12

Cytokine gene polymorphisms influence mucosal cytokine expression, gastric inflammation, and host specific colonisation during Helicobacter pylori infection. Gut (2004) 2.12

Type 2 diabetes and tuberculosis in a dynamic bi-national border population. Epidemiol Infect (2006) 2.09

Higher blood flow and circulating NO products offset high-altitude hypoxia among Tibetans. Proc Natl Acad Sci U S A (2007) 2.07

Acute sensorineural deafness in Lassa fever. JAMA (1990) 2.02

Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II-A trial. Circulation (1990) 2.01

Ribose facilitates thallium-201 redistribution in patients with coronary artery disease. J Nucl Med (1991) 2.00

Serologic and immunologic studies in patients with AIDS in North America and Africa. The potential role of infectious agents as cofactors in human immunodeficiency virus infection. JAMA (1987) 1.98

Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther (1999) 1.96

Biologic differences between strains of Ebola virus from Zaire and Sudan. J Infect Dis (1983) 1.94

Autoradiographic study of mannan incorporation into the growing cell walls of Saccharomyces cerevisiae. J Bacteriol (1974) 1.94

Junin virus monoclonal antibodies: characterization and cross-reactivity with other arenaviruses. J Gen Virol (1989) 1.92

Protection of mice against fatal pneumococcal challenge by immunization with pneumococcal surface adhesin A (PsaA). Microb Pathog (1996) 1.91

Filoviridae: a taxonomic home for Marburg and Ebola viruses? Intervirology (1982) 1.89

Pathogenic potential of filoviruses: role of geographic origin of primate host and virus strain. J Infect Dis (1992) 1.84

A new rapid slide test for infectious mononucleosis. JAMA (1965) 1.82

Intravenous levetiracetam in the treatment of benzodiazepine refractory status epilepticus. J Neurol Neurosurg Psychiatry (2007) 1.80

Diagnosis of Ebola haemorrhagic fever by RT-PCR in an epidemic setting. J Med Virol (2000) 1.79

Physicochemical inactivation of Lassa, Ebola, and Marburg viruses and effect on clinical laboratory analyses. J Clin Microbiol (1984) 1.78

Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol (1999) 1.76

Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA (1995) 1.74

Effective vaccine for lassa fever. J Virol (2000) 1.74

Crimean Congo-haemorrhagic fever treated with oral ribavirin. Lancet (1995) 1.72

Nucleotide sequence of the glycoprotein gene and intergenic region of the Lassa virus S genome RNA. Virology (1986) 1.69

Evaluation of the polymerase chain reaction for diagnosis of Lassa virus infection. Am J Trop Med Hyg (1993) 1.66

Synthetic peptide immunoassay distinguishes HIV type 1 and HIV type 2 infections. Science (1987) 1.66

Isolation of black creek canal virus, a new hantavirus from Sigmodon hispidus in Florida. J Med Virol (1995) 1.65

The surrogate light chain in B-cell development. Immunol Today (1993) 1.64

Dense growth of aerobic bacteria in a bench-scale fermentor. Biotechnol Bioeng (1976) 1.62

Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines. Clin Cancer Res (2001) 1.62

Relation between circadian patterns in levels of circulating lipoprotein(a), fibrinogen, platelets, and related lipid variables in men. Am Heart J (2000) 1.58

Wound infection by an indigenous Pseudomonas pseudomallei-like organism isolated from the soil: case report and epidemiologic study. J Infect Dis (1977) 1.57

Variability in the measurement of regional left ventricular wall motion from contrast angiograms. Circulation (1983) 1.55

Analysis of the SlyA-controlled expression, subcellular localization and pore-forming activity of a 34 kDa haemolysin (ClyA) from Escherichia coli K-12. Mol Microbiol (1999) 1.55

Human-to-human transmission of Pseudomonas pseudomallei. Ann Intern Med (1975) 1.52

A prospective study of maternal and fetal outcome in acute Lassa fever infection during pregnancy. BMJ (1988) 1.51

Endoscopic evaluation of exercise-induced pulmonary hemorrhage and chronic obstructive pulmonary disease in association with poor performance in racing Standardbreds. J Am Vet Med Assoc (1990) 1.51

Dynamic mechanisms in human coronary stenosis. Circulation (1984) 1.49

Longitudinal cohort study of the epidemiology of malaria infections in an area of intense malaria transmission I. Description of study site, general methodology, and study population. Am J Trop Med Hyg (1999) 1.49

Secretion of cell-wall glycoproteins by yeast protoplasts. Effect of 2-deoxy-D-glucose and cycloheximide. Biochem J (1970) 1.48

CD3+CD8+ cell levels as predictors of transmission in human immunodeficiency virus-infected couples: a report from the heterosexual HIV transmission study. Int J Infect Dis (1998) 1.48

Lack of DNA synthesis among CD34+ cells in cord blood and in cytokine-mobilized blood. Br J Haematol (1996) 1.48

Hepatitis G virus in Karachi, Pakistan. Lancet (1996) 1.47

Extreme sensitivity of enveloped viruses, including herpes simplex, to long-chain unsaturated monoglycerides and alcohols. Antimicrob Agents Chemother (1979) 1.47

Arrhythmia in hypertrophic cardiomyopathy. II: Comparison of amiodarone and verapamil in treatment. Br Heart J (1981) 1.46

SlyA, a regulatory protein from Salmonella typhimurium, induces a haemolytic and pore-forming protein in Escherichia coli. Mol Gen Genet (1995) 1.45

Arterial hypoxemia following the administration of sublingual nitroglycerin. Am Heart J (1978) 1.44

The nucleoprotein gene of Ebola virus: cloning, sequencing, and in vitro expression. Virology (1989) 1.42

Effect of surgical repair on the neurologic function in infants with lipomeningocele. Pediatr Neurosurg (1993) 1.40

Epidemiology and control of Lassa fever. Curr Top Microbiol Immunol (1987) 1.40

Modulation of adenylate cyclase of human platelets by phorbol ester. Impairment of the hormone-sensitive inhibitory pathway. Eur J Biochem (1985) 1.39

HFRS after a wild rodent bite in the Haute-Savoie--and risk of exposure to Hantaan-like virus in a Paris laboratory. Lancet (1984) 1.38

Coronary arterial-right heart fistulae. Long-term observations in seven patients. Circulation (1973) 1.37

Viral hemorrhagic fever antibodies in Nigerian populations. Am J Trop Med Hyg (1988) 1.36

Detecting 2009 pandemic influenza A (H1N1) virus infection: availability of diagnostic testing led to rapid pandemic response. Clin Infect Dis (2011) 1.36

Antigenic relatedness between arenaviruses defined at the epitope level by monoclonal antibodies. J Gen Virol (1991) 1.35

Public health considerations in the management of meningococcal disease. Ann Intern Med (1975) 1.32

Preparing for pandemic influenza: the need for enhanced surveillance. Emerg Infect Dis (1999) 1.32

Demonstration of cGMP-dependent protein kinase and cGMP-dependent phosphorylation in cell-free extracts of platelets. Eur J Biochem (1986) 1.31

Extracellular beta-glucanases of the yeast, Saccharomyces cerevisiae. Biochim Biophys Acta (1973) 1.31

Lassa virus hepatitis: a study of fatal Lassa fever in humans. Am J Trop Med Hyg (1986) 1.31

Risk factors for typhoid fever in an endemic setting, Karachi, Pakistan. Epidemiol Infect (1998) 1.29

Trends in disease caused by Neisseria meningitidis: 1972 and 1973. J Infect Dis (1974) 1.29

Hantaan virus: identification of virion proteins. J Gen Virol (1984) 1.27

HIV antibody seroprevalence and associated risk factors in sex workers, drug users, and prisoners in Sindh, Pakistan. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.26

Safe intensive-care management of a severe case of Lassa fever with simple barrier nursing techniques. Lancet (1985) 1.26

Monoclonal antibodies to three strains of hantaviruses: Hantaan, R22, and Puumala. Arch Virol (1991) 1.26

Protection of guinea pigs from Lassa fever by vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of Lassa virus. Virology (1989) 1.25

Nucleotide sequence of the Lassa virus (Josiah strain) S genome RNA and amino acid sequence comparison of the N and GPC proteins to other arenaviruses. Virology (1989) 1.25